GRI Bio annual r&d spending
2020
2021
2022
2023
2024
2025
GRI Bio R&D Spending Growth & History (GRI)
GRI Bio's r&d spending was $6.8M for fiscal 2025.
View full GRI Bio company overviewGRI Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.8M | $3.1M | +80.97% |
| 2024 | 2024-12-31 | $3.8M | $536,000 | +16.58% |
| 2023 | 2023-12-31 | $3.2M | $3.0M | +1235.54% |
| 2022 | 2022-12-31 | $242,000 | −$4.9M | −95.33% |
| 2021 | 2021-12-31 | $5.2M | $1.5M | +39.92% |
| 2020 | 2020-12-31 | $3.7M | — | — |
GRI Bio quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $407,000 | −$1.5M | −78.34% |
| Q1 2026 | 2026-03-31 | $361,000 | −$1.3M | −77.99% |
| Q4 2025 | 2025-12-31 | $1.5M | $698,000 | +83.79% |
| Q3 2025 | 2025-09-30 | $1.8M | $644,000 | +57.24% |
| Q2 2025 | 2025-06-30 | $1.9M | $1.0M | +114.25% |
| Q1 2025 | 2025-03-31 | $1.6M | $707,000 | +75.78% |
| Q4 2024 | 2024-12-31 | $833,000 | −$214,000 | −20.44% |
| Q3 2024 | 2024-09-30 | $1.1M | −$64,000 | −5.38% |
| Q2 2024 | 2024-06-30 | $877,000 | −$3,000 | −0.34% |
| Q1 2024 | 2024-03-31 | $933,000 | $817,000 | +704.31% |
| Q4 2023 | 2023-12-31 | $1.0M | — | — |
| Q3 2023 | 2023-09-30 | $1.2M | $1.1M | +1787.30% |
| Q2 2023 | 2023-06-30 | $880,000 | $821,000 | +1391.53% |
| Q1 2023 | 2023-03-31 | $116,000 | −$1.2M | −90.87% |
| Q3 2022 | 2022-09-30 | $63,000 | −$152,000 | −70.70% |
| Q2 2022 | 2022-06-30 | $59,000 | −$1.1M | −95.09% |
| Q1 2022 | 2022-03-31 | $1.3M | −$501,000 | −28.27% |
| Q4 2021 | 2021-12-31 | $2.0M | $715,000 | +55.73% |
| Q3 2021 | 2021-09-30 | $215,000 | −$518,000 | −70.67% |
| Q2 2021 | 2021-06-30 | $1.2M | $394,000 | +48.76% |
| Q1 2021 | 2021-03-31 | $1.8M | $889,000 | +100.68% |
| Q4 2020 | 2020-12-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $733,000 | — | — |
| Q2 2020 | 2020-06-30 | $808,000 | — | — |
| Q1 2020 | 2020-03-31 | $883,000 | — | — |
GRI Bio r&d spending trends
Over the last five fiscal years, GRI Bio's r&d spending increased from $3.7M to $6.8M, a change of $3.1M. The latest reported quarter, Q2 2026, shows $407,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GRI Bio source filings ↗